Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
[6] People with certain conditions such as significant lipodystrophy or a history of skin reactions to injectable medications may require additional clinical input before beginning treatment
This usually gets better over time as the body adjusts to the medication
The GLP-1 plotter tool can help track progress visually over the course of a long protocol
During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function
Tirzepatide (Mounjaro) What It Is: Tirzepatide is a GLP-1/GIP receptor agonist that combines the effects of GLP-1 (glucagon-like peptide) and GIP (gastric inhibitory peptide)
